Trial ID or NCT#
NCT04508725
Status
RECRUITING
Purpose
To assess whether changes in quantitative tumor perfusion parameters after 3 weeks of treatment, as measured by power doppler ultrasound, can predict initial objective response, defined by current standard-of-care, to therapy at 12 weeks after start of treatment
Official Title
Early Therapeutic Monitoring of Response to Therapy With Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)
Eligibility Criteria
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Investigator(s)
Alice C. Fan
Medical oncologist,
Genitourinary specialist
Assistant Professor of Medicine (Oncology) and, by courtesy, of Urology at the Stanford University Medical Center
Jeremy Dahl
Contact us to find out if this trial is right for you.
CONTACT
Christian Hoerner, PhD
(650) 721-3206
View on ClinicalTrials.gov